Signature(s)
Summary sheet
Sanofi-Aventis
The project concerns the design, construction or modernisation, and the equipment of several buildings providing facilities for pharmacological research, product development facilities and office space in Europe.
The project aims at regrouping and reorganizing the promoter’s R&D activities in order to optimize the use of premises and equipments and facilitate the synergies between different therapeutic areas. It concerns the design, construction or modernisation, and the equipment of several buildings providing facilities for pharmacological research and office space in Europe. The facilities will be located in France, Germany, United Kingdom, Spain and Italy, mostly in the promoter’s existing R&D sites.
The sub-projects fall under Annex II of the directive EU/97/11 amended by Directive 2003/35/EC on Environmental Impact Assessment (EIA). The determination made by the competent authorities for requesting (or not) an EIA on the basis of Annex III of the Directive and actual/possible significant impacts on protected flora and fauna (Habitats’ and Birds’ Directives) has been verified during project appraisal.
The promoter is a private company not operating in the Utilities sector, and is thus not covered by EU Directives on procurement. Procedures followed have been verified during appraisal.
Disclaimer
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).
General enquiries and comments
The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
Alternatively, the EIB can be contacted through its external offices.
Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.
Media enquiries
Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.
Complaints mechanism
Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.
Zero tolerance against fraud and corruption
The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Fraud and Investigation division. All complaints will be treated as strictly confidential and handled in line with the EIB investigation procedures and the Anti-Fraud Policy.
Related publications